Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts

Steffan T. Nawrocki, Christiane J. Bruns, Matthew T. Harbison, Richard J Bold, Bridget Sweeney Gotsch, James L. Abbruzzese, Peter Elliott, Julian Adams, David J. McConkey

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Recent studies have shown that the transcription factor, nuclear factor κB (NF-κB), regulates critical survival pathways in a variety of different cell types, including human pancreatic cancer cells. The activation of NF-κB is controlled by proteasome-mediated degradation of its endogenous polypeptide inhibitor, inhibitor of nuclear factor κBα. We investigated the effects of PS-341, a peptide boronate inhibitor of the proteasome in human pancreatic cancer cells in vitro and in vivo. Comparison of PS-341's effects on the growth of eight different human pancreatic cancer cell lines revealed marked heterogeneity in drug responsiveness, ranging from highly resistant (IC50 > 10 μM; Panc-48, HS766T, and Mia-PaCa-2) to extremely sensitive (IC50 < 40 nM; L3.6pl, Hpaf2, and BxPC3). However, these effects did not correlate with differential inhibition of NF-κB activation. Direct quantification of apoptosis revealed that PS-341's effects on cell growth largely correlated with sensitivity to programmed cell death. Evaluation of PS-341's effects on established orthotopic tumor xenografts demonstrated that biweekly intravenous administration of the maximum-tolerated dose of the drug (1 mg/kg) led to significant reductions in the volumes of L3.6pl tumors but not Mia-PaCa-2 tumors. Laser scanning cytometer-mediated quantification of drug-induced apoptosis in the xenografts confirmed that PS-341 induced DNA fragmentation and activation of caspase-3 in L3.6pl tumors but not in Mia-PaCa-2 tumors. However, histological examination of drug-treated tumors revealed extensive central necrosis and reductions in microvessel density and VEGF expression in both tumor types. Taken together, our results demonstrate that PS-341 inhibits the growth of human pancreatic tumors via direct effects on tumor cells and indirect effects on the tumor vasculature.

Original languageEnglish (US)
Pages (from-to)1243-1253
Number of pages11
JournalMolecular Cancer Therapeutics
Volume1
Issue number14
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Proteasome Inhibitors
Heterografts
Apoptosis
Neoplasms
Pancreatic Neoplasms
Pharmaceutical Preparations
Inhibitory Concentration 50
Growth
Peptides
Critical Pathways
Maximum Tolerated Dose
DNA Fragmentation
Proteasome Endopeptidase Complex
Microvessels
Tumor Burden
Caspase 3
Intravenous Administration
Vascular Endothelial Growth Factor A
Bortezomib
Lasers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Drug Discovery
  • Pharmacology

Cite this

Nawrocki, S. T., Bruns, C. J., Harbison, M. T., Bold, R. J., Gotsch, B. S., Abbruzzese, J. L., ... McConkey, D. J. (2002). Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Molecular Cancer Therapeutics, 1(14), 1243-1253.

Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. / Nawrocki, Steffan T.; Bruns, Christiane J.; Harbison, Matthew T.; Bold, Richard J; Gotsch, Bridget Sweeney; Abbruzzese, James L.; Elliott, Peter; Adams, Julian; McConkey, David J.

In: Molecular Cancer Therapeutics, Vol. 1, No. 14, 12.2002, p. 1243-1253.

Research output: Contribution to journalArticle

Nawrocki, ST, Bruns, CJ, Harbison, MT, Bold, RJ, Gotsch, BS, Abbruzzese, JL, Elliott, P, Adams, J & McConkey, DJ 2002, 'Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts', Molecular Cancer Therapeutics, vol. 1, no. 14, pp. 1243-1253.
Nawrocki, Steffan T. ; Bruns, Christiane J. ; Harbison, Matthew T. ; Bold, Richard J ; Gotsch, Bridget Sweeney ; Abbruzzese, James L. ; Elliott, Peter ; Adams, Julian ; McConkey, David J. / Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. In: Molecular Cancer Therapeutics. 2002 ; Vol. 1, No. 14. pp. 1243-1253.
@article{26f8e7b47f8c46aa9f30371911a15987,
title = "Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts",
abstract = "Recent studies have shown that the transcription factor, nuclear factor κB (NF-κB), regulates critical survival pathways in a variety of different cell types, including human pancreatic cancer cells. The activation of NF-κB is controlled by proteasome-mediated degradation of its endogenous polypeptide inhibitor, inhibitor of nuclear factor κBα. We investigated the effects of PS-341, a peptide boronate inhibitor of the proteasome in human pancreatic cancer cells in vitro and in vivo. Comparison of PS-341's effects on the growth of eight different human pancreatic cancer cell lines revealed marked heterogeneity in drug responsiveness, ranging from highly resistant (IC50 > 10 μM; Panc-48, HS766T, and Mia-PaCa-2) to extremely sensitive (IC50 < 40 nM; L3.6pl, Hpaf2, and BxPC3). However, these effects did not correlate with differential inhibition of NF-κB activation. Direct quantification of apoptosis revealed that PS-341's effects on cell growth largely correlated with sensitivity to programmed cell death. Evaluation of PS-341's effects on established orthotopic tumor xenografts demonstrated that biweekly intravenous administration of the maximum-tolerated dose of the drug (1 mg/kg) led to significant reductions in the volumes of L3.6pl tumors but not Mia-PaCa-2 tumors. Laser scanning cytometer-mediated quantification of drug-induced apoptosis in the xenografts confirmed that PS-341 induced DNA fragmentation and activation of caspase-3 in L3.6pl tumors but not in Mia-PaCa-2 tumors. However, histological examination of drug-treated tumors revealed extensive central necrosis and reductions in microvessel density and VEGF expression in both tumor types. Taken together, our results demonstrate that PS-341 inhibits the growth of human pancreatic tumors via direct effects on tumor cells and indirect effects on the tumor vasculature.",
author = "Nawrocki, {Steffan T.} and Bruns, {Christiane J.} and Harbison, {Matthew T.} and Bold, {Richard J} and Gotsch, {Bridget Sweeney} and Abbruzzese, {James L.} and Peter Elliott and Julian Adams and McConkey, {David J.}",
year = "2002",
month = "12",
language = "English (US)",
volume = "1",
pages = "1243--1253",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts

AU - Nawrocki, Steffan T.

AU - Bruns, Christiane J.

AU - Harbison, Matthew T.

AU - Bold, Richard J

AU - Gotsch, Bridget Sweeney

AU - Abbruzzese, James L.

AU - Elliott, Peter

AU - Adams, Julian

AU - McConkey, David J.

PY - 2002/12

Y1 - 2002/12

N2 - Recent studies have shown that the transcription factor, nuclear factor κB (NF-κB), regulates critical survival pathways in a variety of different cell types, including human pancreatic cancer cells. The activation of NF-κB is controlled by proteasome-mediated degradation of its endogenous polypeptide inhibitor, inhibitor of nuclear factor κBα. We investigated the effects of PS-341, a peptide boronate inhibitor of the proteasome in human pancreatic cancer cells in vitro and in vivo. Comparison of PS-341's effects on the growth of eight different human pancreatic cancer cell lines revealed marked heterogeneity in drug responsiveness, ranging from highly resistant (IC50 > 10 μM; Panc-48, HS766T, and Mia-PaCa-2) to extremely sensitive (IC50 < 40 nM; L3.6pl, Hpaf2, and BxPC3). However, these effects did not correlate with differential inhibition of NF-κB activation. Direct quantification of apoptosis revealed that PS-341's effects on cell growth largely correlated with sensitivity to programmed cell death. Evaluation of PS-341's effects on established orthotopic tumor xenografts demonstrated that biweekly intravenous administration of the maximum-tolerated dose of the drug (1 mg/kg) led to significant reductions in the volumes of L3.6pl tumors but not Mia-PaCa-2 tumors. Laser scanning cytometer-mediated quantification of drug-induced apoptosis in the xenografts confirmed that PS-341 induced DNA fragmentation and activation of caspase-3 in L3.6pl tumors but not in Mia-PaCa-2 tumors. However, histological examination of drug-treated tumors revealed extensive central necrosis and reductions in microvessel density and VEGF expression in both tumor types. Taken together, our results demonstrate that PS-341 inhibits the growth of human pancreatic tumors via direct effects on tumor cells and indirect effects on the tumor vasculature.

AB - Recent studies have shown that the transcription factor, nuclear factor κB (NF-κB), regulates critical survival pathways in a variety of different cell types, including human pancreatic cancer cells. The activation of NF-κB is controlled by proteasome-mediated degradation of its endogenous polypeptide inhibitor, inhibitor of nuclear factor κBα. We investigated the effects of PS-341, a peptide boronate inhibitor of the proteasome in human pancreatic cancer cells in vitro and in vivo. Comparison of PS-341's effects on the growth of eight different human pancreatic cancer cell lines revealed marked heterogeneity in drug responsiveness, ranging from highly resistant (IC50 > 10 μM; Panc-48, HS766T, and Mia-PaCa-2) to extremely sensitive (IC50 < 40 nM; L3.6pl, Hpaf2, and BxPC3). However, these effects did not correlate with differential inhibition of NF-κB activation. Direct quantification of apoptosis revealed that PS-341's effects on cell growth largely correlated with sensitivity to programmed cell death. Evaluation of PS-341's effects on established orthotopic tumor xenografts demonstrated that biweekly intravenous administration of the maximum-tolerated dose of the drug (1 mg/kg) led to significant reductions in the volumes of L3.6pl tumors but not Mia-PaCa-2 tumors. Laser scanning cytometer-mediated quantification of drug-induced apoptosis in the xenografts confirmed that PS-341 induced DNA fragmentation and activation of caspase-3 in L3.6pl tumors but not in Mia-PaCa-2 tumors. However, histological examination of drug-treated tumors revealed extensive central necrosis and reductions in microvessel density and VEGF expression in both tumor types. Taken together, our results demonstrate that PS-341 inhibits the growth of human pancreatic tumors via direct effects on tumor cells and indirect effects on the tumor vasculature.

UR - http://www.scopus.com/inward/record.url?scp=0012433771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012433771&partnerID=8YFLogxK

M3 - Article

C2 - 12516957

AN - SCOPUS:0012433771

VL - 1

SP - 1243

EP - 1253

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 14

ER -